Literature DB >> 22328529

ERK2 drives tumour cell migration in three-dimensional microenvironments by suppressing expression of Rab17 and liprin-β2.

Anne von Thun1, Marc Birtwistle, Gabriela Kalna, Joan Grindlay, David Strachan, Walter Kolch, Alexander von Kriegsheim, Jim C Norman.   

Abstract

Upregulation of the extracellular signal-regulated kinase (ERK) pathway has been shown to contribute to tumour invasion and progression. Because the two predominant ERK isoforms (ERK1 and ERK2, also known as MAPK3 and MAPK1, respectively) are highly homologous and have indistinguishable kinase activities in vitro, both enzymes were believed to be redundant and interchangeable. To challenge this view, we show that ERK2 silencing inhibits invasive migration of MDA-MB-231 cells, and re-expression of ERK2 but not ERK1 restores the normal invasive phenotype. A detailed quantitative analysis of cell movement on 3D matrices indicates that ERK2 knockdown impairs cellular motility by decreasing the migration velocity as well as increasing the time that cells spend not moving. Using gene expression arrays we found that the expression of the genes for Rab17 and liprin-β2 was increased by knockdown of ERK2 and restored to normal levels following re-expression of ERK2, but not ERK1. Both play inhibitory roles in the invasive behaviour of three independent cancer cell lines. Importantly, knockdown of either Rab17 or liprin-β2 restores invasiveness of ERK2-depleted cells, indicating that ERK2 drives invasion of MDA-MB-231 cells by suppressing expression of these genes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22328529     DOI: 10.1242/jcs.092916

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  31 in total

1.  Pharmacologic inhibition of MEK signaling prevents growth of canine hemangiosarcoma.

Authors:  Nicholas J Andersen; Brian J Nickoloff; Karl J Dykema; Elissa A Boguslawski; Roman I Krivochenitser; Roe E Froman; Michelle J Dawes; Laurence H Baker; Dafydd G Thomas; Debra A Kamstock; Barbara E Kitchell; Kyle A Furge; Nicholas S Duesbery
Journal:  Mol Cancer Ther       Date:  2013-06-26       Impact factor: 6.261

Review 2.  Identification of estrogen-responsive genes based on the DNA binding properties of estrogen receptors using high-throughput sequencing technology.

Authors:  Kazuhiro Ikeda; Kuniko Horie-Inoue; Satoshi Inoue
Journal:  Acta Pharmacol Sin       Date:  2014-12-15       Impact factor: 6.150

Review 3.  Consequences of Rab GTPase dysfunction in genetic or acquired human diseases.

Authors:  Marcellus J Banworth; Guangpu Li
Journal:  Small GTPases       Date:  2017-12-28

4.  Integrating Transcriptomic Data with Mechanistic Systems Pharmacology Models for Virtual Drug Combination Trials.

Authors:  Anne Marie Barrette; Mehdi Bouhaddou; Marc R Birtwistle
Journal:  ACS Chem Neurosci       Date:  2017-10-06       Impact factor: 4.418

5.  Rigidity controls human desmoplastic matrix anisotropy to enable pancreatic cancer cell spread via extracellular signal-regulated kinase 2.

Authors:  R Malik; T Luong; X Cao; B Han; N Shah; J Franco-Barraza; L Han; V B Shenoy; P I Lelkes; E Cukierman
Journal:  Matrix Biol       Date:  2018-11-07       Impact factor: 11.583

6.  Surfen-mediated blockade of extratumoral chondroitin sulfate glycosaminoglycans inhibits glioblastoma invasion.

Authors:  Meghan T Logun; Kallie E Wynens; Gregory Simchick; Wujun Zhao; Leidong Mao; Qun Zhao; Subhas Mukherjee; Daniel J Brat; Lohitash Karumbaiah
Journal:  FASEB J       Date:  2019-08-09       Impact factor: 5.191

7.  Rab17 inhibits the tumourigenic properties of hepatocellular carcinomas via the Erk pathway.

Authors:  Kejia Wang; Zhujun Mao; Li Liu; Ronghua Zhang; Qing Liang; Yaokang Xiong; Wenjun Yuan; Li Wei
Journal:  Tumour Biol       Date:  2015-02-24

8.  Growth arrest signaling of the Raf/MEK/ERK pathway in cancer.

Authors:  Jong-In Park
Journal:  Front Biol (Beijing)       Date:  2014-02

9.  ERK1/2 blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition.

Authors:  Janine M Buonato; Matthew J Lazzara
Journal:  Cancer Res       Date:  2013-10-09       Impact factor: 12.701

10.  Inflammasome priming by lipopolysaccharide is dependent upon ERK signaling and proteasome function.

Authors:  Mohammed G Ghonime; Obada R Shamaa; Srabani Das; Ramadan A Eldomany; Teresa Fernandes-Alnemri; Emad S Alnemri; Mikhail A Gavrilin; Mark D Wewers
Journal:  J Immunol       Date:  2014-03-12       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.